Considering that NRF2 is a transcription factor that orchestrates the expression of cytoprotective genes [147] and that mRNA and protein synthesis represent events dependent on adequate cellular metabolic homeostasis, which is compromised in neurodegenerating neurons, the potential therapeutic use of NRF2 activators to treat cognitive impairment resulting from neurodegenerative conditions appears to be unlikely. The gene discussed is NFE2L2; the disease is Cognitive impairment.